Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 4/20 | 0.78 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.41 |
| ▸ | CA2 | P00918 | 4/20 | 0.40 |
| ▸ | CA1 | P00915 | 3/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 3/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | IKBKB | O14920 | 1/20 | 0.38 |
| ▸ | CHUK | O15111 | 1/20 | 0.38 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12482725 | 0.90 | CHRNA7 (0.83) | CHRNA7PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL12483812 | 0.88 | CHRNA7 (0.81) | CHRNA7PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL12483106 | 0.87 | CHRNA7 (0.79) | CHRNA7PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL12483102 | 0.87 | CHRNA7 (0.79) | CHRNA7PTGS2PTGS1CA2CA9 | |
| SCHEMBL12483469 | 0.87 | CHRNA7 (1.00) | CHRNA7PTGS2PTGS1CA2CA1 | |
| SCHEMBL12483998 | 0.87 | CHRNA7 (0.58) | CHRNA7PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL12483527 | 0.87 | CHRNA7 (0.69) | CHRNA7PTGS2PTGS1CA2CA1 | |
| SCHEMBL17976831 | 0.87 | CHRNA7 (0.74) | CHRNA7PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL12484103 | 0.87 | CHRNA7 (0.59) | CHRNA7PTGS2CA2CA1CA9 | |
| SCHEMBL12482673 | 0.86 | CHRNA7 (0.78) | CHRNA7PTGS2PTGS1CA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2678327-B9 | HETEROARYL DERIVATIVES AS ALPHA7 NACHR MODULATORS | LUPIN LTD (IN) | 2016-12-28 | — | — | EP | claimed |
| EP-2678327-B1 | HETEROARYL DERIVATIVES AS ALPHA7 NACHR MODULATORS | LUPIN LTD (IN) | 2016-08-17 | — | — | EP | claimed |
| US-9393247-B2 | Heteroaryl derivatives as alpha7 nAChR modulators | LUPIN LIMITED (IN) | 2016-07-19 | — | — | US | claimed |
| US-20150231143-A1 | Heteroaryl Derivatives as Alpha7 NACHR Modulators | LUPIN LIMITED (IN) | 2015-08-20 | — | — | US | claimed |
| US-9072731-B2 | Heteroaryl derivatives as alpha7 nAChR modulators | LUPIN LIMITED (IN) | 2015-07-07 | — | — | US | claimed |
| EP-2678327-A1 | HETEROARYL DERIVATIVES AS ALPHA7 NACHR MODULATORS | Lupin Limited (IN) | 2014-01-01 | — | — | EP | claimed |
| US-20130331387-A1 | HETEROARYL DERIVATIVES AS ALPHA7 NACHR MODULATORS | LUPIN LIMITED (IN) | 2013-12-12 | — | — | US | claimed |
| CN-103402994-A | Heteroaryl derivatives as alpha7 NACHR modulators | LUPIN LTD | 2013-11-20 | — | — | CN | claimed |
| WO-2012114285-A9 | HETEROARYL DERIVATIVES AS ALPHA7 NACHR MODULATORS | LUPIN LIMITED (IN) | 2012-10-18 | — | — | WO | claimed |
| WO-2012114285-A1 | HETEROARYL DERIVATIVES AS ALPHA7 NACHR MODULATORS | LUPIN LIMITED (IN) | 2012-08-30 | — | — | WO | claimed |
| EP-2678327-B9 | HETEROARYL DERIVATIVES AS ALPHA7 NACHR MODULATORS | LUPIN LTD (IN) | 2016-12-28 | — | — | EP | disclosed |
| EP-2678327-B1 | HETEROARYL DERIVATIVES AS ALPHA7 NACHR MODULATORS | LUPIN LTD (IN) | 2016-08-17 | — | — | EP | disclosed |
| US-9393247-B2 | Heteroaryl derivatives as alpha7 nAChR modulators | LUPIN LIMITED (IN) | 2016-07-19 | — | — | US | disclosed |
| US-20150231143-A1 | Heteroaryl Derivatives as Alpha7 NACHR Modulators | LUPIN LIMITED (IN) | 2015-08-20 | — | — | US | disclosed |
| US-9072731-B2 | Heteroaryl derivatives as alpha7 nAChR modulators | LUPIN LIMITED (IN) | 2015-07-07 | — | — | US | disclosed |
| EP-2678327-A1 | HETEROARYL DERIVATIVES AS ALPHA7 NACHR MODULATORS | Lupin Limited (IN) | 2014-01-01 | — | — | EP | disclosed |
| US-20130331387-A1 | HETEROARYL DERIVATIVES AS ALPHA7 NACHR MODULATORS | LUPIN LIMITED (IN) | 2013-12-12 | — | — | US | disclosed |
| CN-103402994-A | Heteroaryl derivatives as alpha7 NACHR modulators | LUPIN LTD | 2013-11-20 | — | — | CN | disclosed |
| WO-2012114285-A9 | HETEROARYL DERIVATIVES AS ALPHA7 NACHR MODULATORS | LUPIN LIMITED (IN) | 2012-10-18 | — | — | WO | disclosed |
| WO-2012114285-A1 | HETEROARYL DERIVATIVES AS ALPHA7 NACHR MODULATORS | LUPIN LIMITED (IN) | 2012-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130331387-A1 | HETEROARYL DERIVATIVES AS ALPHA7 NACHR MODULATORS | CHRNA7, CHRM1, CHRM2 | CHRNA7 1/4885PIK3CD 3543/4885PIK3CA 3318/4885 |
| US-20150231143-A1 | Heteroaryl Derivatives as Alpha7 NACHR Modulators | CHRNA7, CHRM1, CHRM2 | CHRNA7 1/4885PIK3CD 3686/4885PIK3CA 3438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.